



Sofia[®]2

Technical Bulletin

Sofia 2 Lyme Fluorescent Immunoassay (FIA)

The recommended CPT[®] code for the Sofia 2 Lyme FIA assay is:

CPT Code	Description
86618 QW*	Antibody; Borrelia burgdorferi (Lyme disease)

*"QW" modifier is added to report use of CLIA-waived test system(s) for Medicare/Medicaid claims.

For the Medicare Clinical Laboratory Fee Schedule, go to <https://www.cms.gov>

Relevant CPT/CMS Guidance:

CPT 2021 Professional Edition p. 654:

- "...if multiple assays are performed for antibodies of different immunoglobulin classes, each assay should be coded separately."

NCCI Manual 2021 Ch.10, Section M.15 (pp. X-25-X-26)

- "15. In the case of tests for infectious agents, methodologies include detection by immunofluorescence, immunoassay, or nucleic acid probe techniques. A single laboratory procedure shall be reported as one unit of service whether it generates one or multiple results. CPT codes that test for a single infectious agent that employ one procedure, one methodology, or one test kit are reported with one unit of service.

CPT codes that test for multiple infectious agents are reported with one unit of service if one procedure, one methodology, or one test kit is used to perform the test (e.g., 87300, 87451, 87800, 87801). When multiple procedures, multiple methodologies, or multiple kits are medically necessary and used to perform a test for multiple infectious agents, the units of service reported for CPT codes that identify multiple infectious agents equals the number of different procedures, methodologies, or kits used to perform the test.

For example, if a provider/supplier tests for 5 different species of an infectious agent using a single multiple-result test kit, only 1 unit of service for that test kit may be reported. However, if a provider/supplier tests for 3 different species of an infectious agent by using 3 different single result test kits, the provider/supplier may report 3 UOS of the appropriate CPT code."

Quidel Corporation recommends that providers contact their contracted payors to determine appropriate coding and charge or payment levels prior to submitting claims.

For reimbursement inquiries, please contact CodeMap® at guidel@codemap.com or 312.291.8408. You may also visit: <https://www.codemap.com/guidel/>. If you have any questions regarding the use of this product, please contact Quidel Technical Support at 1.800.874.1517 (in the U.S.) or technicalsupport@quidel.com. If outside the U.S., further information can be obtained from your distributor, or directly from Quidel at one of the numbers listed below. Reference **quidel.com** to see more options for Support.

Country	Phone	E-Mail Address
Europe, Middle East and Africa	+353 (91) 412 474 (main) 0 1800 200441 (toll free)	emeatechnicalsupport@quidel.com
Austria	+43 316 231239	
Belgium	+32 (2) 793 0180	
France	0 (805) 371674	
Germany	+49 (0) 7154 1593912	
Netherlands	0 800 0224198	
Switzerland	0 800 554864	
United Kingdom	0 800 3688248	
Ireland	+353 (91) 412 474	
Italy	+39 (800) 620 549	
North America, Asia-Pacific, Latin America	858.552.1100	technicalsupport@quidel.com
Canada	437.266.1704 (main) 888.415.8764 (toll free)	technicalsupport@quidel.com
China	0400 920 9366 or +86 021 3217 8300	chinatechnicalservice@quidel.com

You may also visit our website at **quidel.com** for information on Quidel's line of Rapid Diagnostics, Molecular Diagnostics, Cell Culture and Specialty Products (Bone Health and Autoimmune & Complement). Other product information available on our website includes: CPT codes, CLSI procedure guides, SDS, and Package Inserts.

This information is being provided as a reference, for informational purposes only, with no express or implied warranty and does not purport to provide legal or certified coding advice. **Under Federal and State law, it is the individual provider's responsibility to determine appropriate coding, charges and claims for a particular service.** Policies regarding appropriate coding and payment levels can vary greatly from payer to payer and change over time. Quidel Corporation strongly recommends that providers contact their contracted payers to determine appropriate coding and charge or payment levels prior to submitting claims.

TB20319100EN00 (05/21)